Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- GSK/Vir’s COVID-19 Drug Up for MHLW Panel Review on Sept. 27
September 22, 2021
- All 4 Contenders in LDP Leadership Race Vow to Expand COVID-19 Measures
September 21, 2021
- MHLW Panel to Discuss Whether Govt Should Investigate Safety of COVID-19 Vaccines
September 21, 2021
- Japan to Start Discussions in October on Reinstating HPV Vaccine Recommendation
September 21, 2021
- Prevent Avigan Use in Potentially Pregnant COVID-19 Patients: Minister
September 21, 2021
- Chuikyo Raises No Objections to MHLW Proposal on Revision of CEA Analysis Process
September 17, 2021
- Japan to Start Pilot Project for Home Use of Antibody Cocktail: Minister
September 17, 2021
- Daiichi Sankyo Missed Goal on CEA Data Submission, but Delay Deemed Reasonable
September 16, 2021
- DPO Minutes to Be Disclosed 2 Months after Chuikyo General Assembly
September 16, 2021
- Tainted Moderna Jabs Run Afoul of PMD Law: Minister
September 16, 2021
- Kazuhito Ihara to Helm Health Policy Bureau; Vice Minister Tarumi to Stay
September 15, 2021
- Japan Eyes Legal System to Ensure Generic Supplies in New Industry Vision, Key Official Says It’s Difficult with Companies’ Own Efforts Alone
September 15, 2021
- MHLW Unapproved Drug Panel Agrees on High Needs for 7 Additional Indications for Fertility Treatments
September 14, 2021
- 16,680 Doses Ruined in Workplace Inoculations; Bayer, Otsuka Too
September 14, 2021
- COVID-19 Jabs Need 3 Month Interval after Antibody Cocktail Use: MHLW
September 14, 2021
- Panel OKs 37 More COVID-19 Jab Health Damage Claims for Compensation
September 14, 2021
- Japan Unveils New Pharma Industry Vision, 1st Update in 8 Years
September 14, 2021
- SaMD Would Be Evaluated Like Ordinary Medical Devices: PMDA Official
September 13, 2021
- PMDA Reviewing Safety Risks for Ivermectin, Xeljanz
September 13, 2021
- Causal Link between Deaths and Recalled Batch of Moderna Jab “Indeterminable”
September 13, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…